Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC

Author(s):  
Matthew G. Krebs ◽  
Rajiv Shinde ◽  
Rozana Abdul Rahman ◽  
Rafael Grochot ◽  
Martin Little ◽  
...  
Keyword(s):  
Phase I ◽  
2017 ◽  
Vol 19 (8) ◽  
pp. 1135-1144 ◽  
Author(s):  
Anuradha Banerjee ◽  
Regina I. Jakacki ◽  
Arzu Onar-Thomas ◽  
Shengjie Wu ◽  
Theodore Nicolaides ◽  
...  

2018 ◽  
Vol 127 ◽  
pp. S387-S388
Author(s):  
K. Haslett ◽  
F. Blackhall ◽  
P. Koh ◽  
L. Ashcroft ◽  
M. Asselin ◽  
...  

Lung Cancer ◽  
2018 ◽  
Vol 115 ◽  
pp. S65
Author(s):  
K. Haslett ◽  
F. Blackhall ◽  
P. Koh ◽  
L. Ashcroft ◽  
M. Asselin ◽  
...  

2007 ◽  
Vol 177 (4S) ◽  
pp. 202-202
Author(s):  
Hirotsugu Uemura ◽  
Motoyoshi Tanaka ◽  
Shigeya Uejima ◽  
Takafumi Minami ◽  
Kiyohide Fujimoto ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document